期刊文献+

非那雄胺疗程对良性前列腺增生组织中VEGF表达及MVD计数影响的变化 被引量:2

The Influence of Finasteride on BPH-related Microvessel Density and Vascular Endothelial Growth Factor Expression
下载PDF
导出
摘要 目的通过在前列腺电切(TURP)术前不同时间应用非那雄胺,观察对良性前列腺增生(benignprostate hyperplasia,BPH)组织的微血管相关因素的影响变化,以寻求最佳用药时间。方法将拟行TURP的BPH患者270例,随机分为5组。用药组分别在术前不同时间服用非那雄胺,记录术中出血量;术后检测前列腺组织微血管密度(MVD)和血管内皮生长因子(VEGF)表达。结果对照组术中平均出血量、前列腺组织MVD值、VEGF阳性计数与各实验组比较,P>0.05;与实验2组比较,P<0.05;与实验3组、4组比较,P<0.01。实验2组与3组比较,P<0.05;实验3组与4组比较,P>0.05。结论术前服用非那雄胺2周可减少前列腺组织内血管生成,并可减少TURP术中出血,服药3周效果最佳。 Objective By application of finasteride at different times before the TURP{ transurethral prostatic resection} surgery to observe the BPH-related factors microvascular changes,so as to find the best medication time. Methods Two hundred and seventy patients were randomly divided into 5 groups. The treatment group were taken finasteride at different times before surgery,and the blood loss was recorded in the operation;The microvessel density { MVD } and expression of vascular endothelial growth factor(VEGF) of prostate tissue were detected. Results The average intr- aoperative blood loss, prostate tissue MVD values and VEGF-positive count of the control group were compared with each group. There was statistical significance between the control group and the group 2 ( P 〈 0.05 ) , group 2 and 3 ( P 〈 0. 05 ), the control group and the group 2 and 3 ( P 〈0.01 }. There was no statistical significance between group 3 and 4{ P 〉0.05). Conclusion Taking finasteride for two weeks before the surgery can reduce angiogenesis in prostate tissue and blood loss during TURP;The best medication times is three weeks.
出处 《潍坊医学院学报》 2009年第6期452-454,共3页 Acta Academiae Medicinae Weifang
基金 威海市科技发展计划项目(项目编号:2008093-8)
关键词 BPH TURP 非那雄胺 疗程 MVD VEGF BPH TURP Finasteride Treatment MVD VEGF
  • 相关文献

参考文献7

  • 1李祖广,侯序广,刘衍广,时书库.分区、分单元TURP治疗前列腺增生症100例疗效观察[J].山东医药,2007,47(5):43-44. 被引量:2
  • 2王建业 邵鸿勋.TURP术中出血量的测定[J].中华泌尿外科杂志,1990,11:146-147.
  • 3Sordello S,Bertrand N,Plouet J.Vascular endothelial growth factor is up-regulated in vitro and in vivo by anandrogen[J].Biochem Biophy Res Commun,1998,251(2):287-290.
  • 4Mebust WK,Holtgrewe HL,Cockett ATK,et al.Transurethral prostatectomy:immediate and post-operative complications.A cooperative studies of 13 participating institutions evaluating 3885patients[J].J Urol,1989,141(2):243-248.
  • 5Bailey DM,Foley SJ.Microvacular anatomy in patients with recurrent haematuria related to prostatic hypertrophy[J].J Urol,1999,161(2):225-227.
  • 6McConnel JD,Bruskewitz RC,Walsh PC,et al.The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men benign prostatic hyperplasia[J].N Engl J Med,1998,338(21):557-563.
  • 7Bailey DM,foley SJ,Wedderburn AW.Effect of Finasteride on microvessel density(MVD) in patients with recurrent haematuria related to prostatic hypertrophy[J].J Urol,1999,161(3):363-364.

二级参考文献2

共引文献17

同被引文献25

  • 1Crea G, Santilippo G, Anastasi G, et al. Pre-surgieal finasteride therapy in patients treated endoseopieaUy for benign prostatic hyper- plasia [J]. Urol Int, 2005,74(1) :51-53.
  • 2Lekas AG, Lazaris AC, Chrisofos M, et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia [J]. Urology, 2006,68(2) :436-441.
  • 3Lund L, Emst-Jensen KM, Tcrring N, et al. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study [ J ]. Scand J Urol Nephrol, 2005,39(2) :160-162.
  • 4Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride [J]. Urology, 2001,58(6) :972-976.
  • 5Ozdal OL, Ozden C, Benli K, et al. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P) : a randomized con- trolled study [J]. Prostate Cancer P D, 2005,8(3) :215-218.
  • 6Berardinis ED, Antonini G, Busetto GM, et al. Reduced intraop- erative bleeding during transurethral resection of the prostate : eval- uation of finasteride, vascular endothelial growth factor, and CD34 [J]. Current Prostate Reports, 2005,6 ( 3 ) : 123-127.
  • 7Donohue JF, Hayne D, Karnik U, et al. Randomized, placebo controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks [J]. BJU Int, 2005,96(9) :1319-1322.
  • 8Memis A, Ozden C, Ozdal OL, et al. Effect of finasteride treat- ment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia [J]. Urol Int, 2008,80(2) :177-180.
  • 9Hagstrom S, Trring N, Mller K, et al. Effects of finasteride on vascular endothelial growth factor [ J ]. Scand J Urol Nephrol, 2002,36(3) :182-187.
  • 10AUA practice guidelines committee. AUA guideline on management of benign prostatichyperp lasia (2003). Chapter 1 :diagnosis and treatment recommendations[J]. J Urol,2003,170(2 Pt 1):530-547.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部